Key Takeaways
- Q4 hit by unprecedented Chinese price collapse: Revenue grew 8.6% but EBITDA margin turned negative to 9.37% as Chinese product prices fell 20–50%, forcing liquidation of high-cost inventory at competitive prices.
- FY23 was a strong growth year with a weak finish: Full-year revenue grew 19.77% to ₹1,801.33 crore, but EBITDA margin contracted 451 bps, with the bulk of the damage concentrated in Q4 from inventory and MTM losses.
- Trailing pain extends into Q1 FY24: April and May remained difficult as ~50% of high-cost inventory was still to be liquidated and further price declines continued to hit; management expects the worst to be over by end of Q1.
- FY24 margin guidance is deliberately subdued at 9–10%: Management calls it conservative, citing a "very bad" Chinese situation with prices at 10–15 year lows and an unclear future, while noting that 4–5 built-up products could change results in totality if they perform.
- What to watch next quarter: Whether the high-cost inventory is fully liquidated by June as promised, the pace of the product mix shift toward higher-margin patented and Maharatna products, and any signal that Chinese pricing has found a floor.
The Chinese Price Shock
- Unprecedented collapse: Chinese product prices fell 20% to 50% in the last 4–5 months, with some touching 10–15 year lows that management says it had never seen or anticipated.
- Inventory caught at the worst moment: The company was in expansion mode and had built up large raw-material inventories to run plants including the delayed Dahej plant; when prices collapsed from January onward, that higher-cost inventory had to be sold at prevailing competitive market prices.
- Q4 sales were dominated by high-cost stock: 70% of Q4 sales were of higher-cost inventory, which crushed the gross profit ratio.
- Dealer credit notes compounded the damage: Material sold in February–March at higher prices had to be credit-noted down when prices fell in April–May, because distributors cannot be billed at ₹100 when the price drops to ₹80.
- MTM losses added ~₹14 crore: Mark-to-market provisioning was taken during the year.
- Liquidation is halfway done: Management believes ~50% of high-cost inventory has been liquidated; the remaining ~50% is still to be moved.
- Demand in India remains healthy: Indian demand is "very, very positive" with no downfall; the only worry is the international and Chinese pricing scenario.
Rajesh Aggarwal: "I would say it has been the worst time, when the China has deteriorated so much and deteriorated the value of the products, which we had never imagined. So sometimes there are hits, which you don't imagine."
Margin Walk & Recovery Path
- FY23 margin decline was 451 bps: The increase in cost of raw material consumed versus FY22 was the primary driver, with the major impact occurring in the last quarter.
- Q4 margin was negative despite new product launches: Within the Maharatna category, which contributed ~50% of sales, lower-contributing products sold during the January–March period because more profitable product sales only begin with the season from June.
- Trailing losses to end by Q1 close: April and May were quite difficult due to trailing losses from higher-cost inventory; lower-cost inventory procurement has already started, and from Q2 management hopes there will be no impact of higher inventories.
- Product mix shifts favorably from June: Higher-contributing products begin selling with the season, and patented product sales of ~₹100 crore in FY23 are expected to multiply in FY24.
- Backward integration is on hold: The plant is set up but production will not start until it makes economic sense, because international prices are so low that more backward integration would mean more loss.
- FY24 margin guidance of 9–10% is explicitly conservative: Management does not want to give aggressive numbers given the Chinese situation, but expects performance to be better than guided and notes that 4–5 built-up products could change results in totality once they start performing.
Rajesh Aggarwal: "I don't want to give the higher figures because Chinese situation overall is looking very bad, wherein as I told you that they are almost at 10 years low price, in many products, actually. And the future is not very clear. So that's why we are going a little subdued as the situation improves because it's like a wheel. The wheel is at the lowest level at the moment."
Product Portfolio & Brand Building
- Star performers scaling rapidly: Hachiman grew from ₹21.5 crore in FY21 to ₹67.9 crore in FY23; Shinwa grew from ₹0.78 crore in FY22 to ₹65.3 crore in FY23; both are expected to take a big leap in FY24 along with Kunoichi and Hakama from the Nissan portfolio.
- New launches expected to contribute meaningfully: More mixtures have been registered and launched in recent months; products like Torry, Hachiman, Mission, and Dominant are expected to do very well in FY24.
- Maharatna share targeted at 60%+: Maharatna and Focused Maharatna segments should contribute not less than 60% in FY24, up from ~50%, driving a continuous improvement in product mix and profitability.
- Nissan portfolio expanding: About 6 products planned with Nissan; Shinwa and Hachiman to lead, followed by Kunoichi and Hakama; the overall Nissan portfolio is expected to contribute reasonably well.
- Biologicals and nanos are the next frontier: IIL Biologicals has been launched with a plant and R&D center at Shamli and another R&D center at Chopanki; nanos technology will be taken into the chemical segment as well, with breakthrough technologies expected in both biological and chemical.
- Brand investment underway: Mr. Ajay Devgan has been hired as brand ambassador to promote and build goodwill for the company's products.
- R&D pipeline active: R&D is continuously working on formulation development for new-generation mixtures, backward-integrated technicals, biologicals, and new products.
Capacity Expansion & Plant Updates
- Chopanki plant operational: The project is completed and functioning; technical production has started full-fledged, and new molecules have already been taken out and are in the market.
- Sotanala site acquisition near closure: A new plant at Sotanala, Behror is in the final stages of acquisition, with registry expected in early June; Phase 1 formulations production is targeted by end of FY24, with Phase 2 adding biologicals and technicals.
- Dahej plant starting soon: The plant is set up and expected to start very soon, though backward-integration production will be deferred until international prices recover to levels that make it economically viable.
- R&D pilot plant completed: An R&D pilot plant has been completed at Chopanki.
Export & International Dynamics
- FY23 exports declined on currency and credit constraints: Currency crises in South America, the Middle East, Africa, and CIS countries meant distributors had cash but banks lacked dollars to transfer; Indian insurance companies reduced country and customer limits, forcing the company to curb sales to avoid risk.
- FY24 export target is a doubling: Management expects to double exports this year after the FY23 decline, though gaining market share will require buying new inventory and selling at competitive prices to compete with China.
- Chinese factories are under pressure: Management views the current low-price phase as cyclical and not sustainable; many Chinese factories are closing and liquidating stocks, and a recent exhibition reportedly saw very weak order collection.
- The cycle will turn, but timing is unclear: Management frames the downturn as a cyclical low and expects a recovery, but offers no timeline, noting that "the future is not very clear."
Rajesh Aggarwal: "It's a sustainable situation because every business trend is cyclic. This is the lowest phase, which we are passing through, when the international market or the Chinese market is dumping at very low cost. It is not sustainable for them. Many factories are closing."
Balance Sheet & Capital Allocation
- Interim dividend paid: An interim dividend of ₹3 per share was issued during the year.
- Buyback completed: The company completed a buyback in the last year, which increased promoter holding; there has been no promoter offloading.
- Inventory is sellable, not obsolete: Management states all inventory is sellable with no big old inventory or big hits expected; hits are continuously being taken care of.
- Sales returns remain low: Historically at 3–5% of total sales; the company manages by rotating stock between areas rather than taking absolute returns.
- Q1 FY24 gross sales target: ₹800 crore-plus in gross sales, with the net figure lower after discounts.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Double-digit, 10% to 12% | FY24 |
| EBITDA margin | 9% to 10% (described as conservative) | FY24 |
| High-cost inventory liquidation | Majority liquidated, effort to complete majority in Q1 | Q1 FY24 / FY24 |
| Trailing losses from higher-cost inventory | Finished by end of Q1; no impact from Q2 | End of Q1 FY24 |
| Exports | Double after FY23 decline | FY24 |
| Maharatna + Focused Maharatna contribution | Not less than 60% of sales | FY24 |
| Sotanala plant Phase 1 | Formulations production begins | End of FY24 |
| Patented product sales | Multiply from ~₹100 crore base in FY23 | FY24 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹302 crore, growth of about 8.6% |
| EBITDA margin | Negative 9.37%, due to M2M losses and liquidation of higher cost inventory |
| Revenue (full year FY23) | ₹1,801.33 crore, growth of about 19.77% YoY |
| EBITDA (full year FY23) | ₹121.89 crore |
| EBITDA margin (full year FY23) | Declined by 451 bps YoY |
| Maharatna products sale | ₹78.6 crore, about 51% of formulation sales |
| Insecticide segment revenue | ₹72 crore, 47% of Q4 sales |
| Herbicide segment revenue | ₹43.5 crore, 29% of Q4 sales |
| Fungicide segment revenue | ₹36 crore, 23% of Q4 sales |
| Biologicals and PGRs revenue | ₹0.9 crore, 1% of sales |
| M2M losses (full year FY23) | Around ₹14 crore |
| Higher cost inventory in Q4 sales | 70% of Q4 sales |
| Patented products sales (full year FY23) | About ₹100 crore |
| Closing inventory | About ₹860 crore |
| FY24 revenue growth target | 10% to 12% |
| FY24 EBITDA margin target | 9% to 10% |
| FY24 Maharatna and Focused Maharatna contribution target | Not less than 60% |
| FY24 export expectation | Doubling |
| Q1 FY24 gross sales target | ₹800 crore-plus |
| High-cost inventory liquidated | ~50% liquidated, ~50% still remaining |
| Credit note impact from dealer price protection | ₹15–20 crore hit |
| China price decline | 20% to 50%, some at 10–15 year lows |
| Interim dividend | ₹3 per share |